NCT02539576 - Pharmacokinetics, Safety and Tolerability Study of Abacavir/ Dolutegravir/ Lamivudine Fixed-dose Combination Tablets in Healthy Japanese Subjects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

ABC/DTG/3TC FDC tablet

"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."

Trial Locations (1)

91206

GSK Investigational Site, Glendale